ClinicalTrials.gg
RecruitingNCT07090785Updated Nov 17, 2026

A Study of LY4088044 in Healthy Participants

A Phase 1 interventional study of LY4088044 and LY4088044 in Healthy, sponsored by Eli Lilly and Company. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 17, 2026No longer in New ZealandPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring
  • Have a (BMI) within the range 18.5 to 30 kilogram per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Are individuals assigned female at birth (AFAB) who are pregnant and/or lactating
  • Regularly use known drugs of abuse or show positive findings on urinary drug screening that are not consistent with their medication history
  • Participants with outside of the local laboratory normal range for age and gender, or evidence of iron deficiency, or hemoglobinopathy
  • Participants with estimated (GFR) less than 90 milliliter per minute per 1.73 square meter (mL/min/1.73 m²)
  • Have a 12-lead (ECG) abnormality
  • Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes AND are unable to abide by investigative site smoking restrictions
  • Have an average weekly alcohol intake that exceeds 21 units per week (males less than or equal to 65 years old) and 14 units per week (females and males over 65-year-old, if applicable) and are unwilling to abide by the restrictions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    LY4088044 (Part A)

    Single-ascending dose (SAD) of LY4088044 administered intravenously (IV)

    Drug: LY4088044

  • Placebo comparator
    Placebo (Part A)

    Administered IV

    Drug: Placebo

  • Experimental
    LY4088044 (Part B)

    SAD of LY4088044 administered subcutaneously (SC)

    Drug: LY4088044

  • Placebo comparator
    Placebo (Part B)

    Administered SC

    Drug: Placebo

  • Experimental
    LY4088044 (Part C)

    Multiple-ascending doses (MAD) of LY4088044 administered IV

    Drug: LY4088044

  • Placebo comparator
    Placebo (Part C)

    Administered IV

    Drug: Placebo

Interventions

  • DrugLY4088044

    Administered IV

  • DrugLY4088044

    Administered SC

  • DrugPlacebo

    Administered IV

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Approximately Day 190

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4088044

    PK: Cmax of LY4088044

    Time frame: Baseline up to Approximately Day 190

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY4088044

    PK: AUC of LY4088044

    Time frame: Baseline up to Approximately Day 190

  3. Pharmacodynamics (PD): Protein Levels in Skin Samples

    PD: Percent Decrease in Protein Levels

    Time frame: Baseline up to Approximately Day 190

07

Study locations

3 of 5 sites recruiting
  • Collaborative Neuroscience Network - CNS
    Los Alamitos, California 90720, United States
    Active, not recruiting

    Not enrolling at this site.

  • ICON
    Lenexa, Kansas 66219, United States
    Suspended

    Not enrolling at this site.

  • ICON Early Phase Services
    San Antonio, Texas 78232, United States
    Recruiting
    • · Contact210-283-4156
    • Chinonye Ogbonnaya-Odor · Principal investigator
  • ICON
    Salt Lake City, Utah 84124, United States
    Recruiting
    • · Contact801-269-8200
    • Ahad Sabet · Principal investigator
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
    Recruiting
    • · Contact+65 6413 9811
    • Jeffer Hann Wei Pang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2027 → Aug 2027 and completion Jul 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 29, 2025
StartActual
Jul 24, 2025
Primary completionEst.
Aug 2027was Jul 2027
CompletionEst.
Aug 2027was Jul 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed; no longer in New Zealand. Collaborative Neuroscience Network - CNS is now Active, not recruiting
Show 1 removed
  • New Zealand Clinical Research Christchurch · Christchurch, New Zealand
across 2 updates, Oct 7, 2026 – Nov 17, 2026
Primary completion
Jul 2027→Aug 2027
Nov 17, 2026
Study completion
Jul 2027→Aug 2027
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Collaborative Neuroscience Network - CNS · Los Alamitos, United StatesContact removed •••9494Contact removed (no phone or email listed)
Oct 7, 2026
Show all 2 updates
  1. Nov 17, 2026
    1 site removed; no longer in New Zealand
    Show 1 removed
    • New Zealand Clinical Research Christchurch · Christchurch, New Zealand
    Primary completion Jul 2027→Aug 2027
    Study completion Jul 2027→Aug 2027
    + 1 other change: verification date
  2. Oct 7, 2026
    Collaborative Neuroscience Network - CNS is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Collaborative Neuroscience Network - CNS · Los Alamitos, United StatesContact removed •••9494Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07090785
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Jul 24, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion